

# Phytohealth Corporation

**Taiwan Stock Exchange (symbol:4108)**

**2025 Institutional Investor Conference**

**Established: 1998**

**Stock Exchange Listed: 2008**

**Capitalization: USD 70M**

**Chairperson: Yili Lee**

CEO  
Angel Lee



懷特生技新藥(股)公司  
PhytoHealth Corporation

# Statement

1. Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes.
2. The future projections presented in this document reflect the company's views as of the current date. However, the company is not obligated to update this information in case of any events or changes in the environment.
3. Without the company's permission, the copying, modification, recompilation, reduction, or transmission of any content in this presentation, or the use of any such content for commercial purposes, is strictly prohibited.
4. The content of this presentation includes all entities belonging to the consolidated financial statements.



# Company Profile




懷特生技新藥(股)公司  
PhytoHealth Corporation

***PhytoHealth aims to apply the latest pharmaceutical drug development techniques to innovate natural treatments used for thousands of years in Chinese botanical medicine practices to satisfy the unmet clinical needs.***









# Key milestones of Phytohealth Corporation



懷特生技新藥(股)公司  
PhytoHealth Corporation

# Phytohealth's new drug product development: 2 items have obtained TFDA drug licenses

	Product Function / Indication	Pre-Clinical	Phase I	Phase II	Phase III	NDA	Approval
Launched	懷特血寶® PG2	The world's only prescription drug to treat "Cancer Related Fatigue"					
	懷特痛寶® Oraphine ®	New analgesic (Nalbuphine) oral dosage form drug					
Investigational new drugs	PHN031 ® Prevent osteoporosis	Completed U.S. FDA approval of Phase IIa clinical trial					
	PHN033 Treat diabetic nephropathy	Completed U.S. FDA approval of Phase IIa clinical trial					
	PG2(Combo Therapy)	Start Phase II clinical trial				RWE: Breast /colorectal cancer	



懷特生技新藥(股)公司  
PhytoHealth Corporation

A hand pointing forward with a network overlay of white lines and dots on a light background.

**The global market for botanical and plant-derived drugs has show continual growth over the last decade and is showing promise to continue moving forward at steady pace.**

\*Botanical and Plant-derived Drugs: Global Markets, BCC Research



**\$49B**

USD in 2024

**\$76B**

USD by 2030

**7.3%**

CAGR

# Key factors holding back botanical drug markets



懷特生技新藥(股)公司  
PhytoHealth Corporation





# Our Track Record of Success



## Regulatory Approval

**1st New TFDA License**  
For Prescription Botanical  
Drug issued by TFDA  
(April, 2010)

**1st PIC/S GMP Certified**  
Botanical Drug API Plant  
Certified by TFDA  
(September, 2016)

**2 of 10 New Drugs**  
approved by TFDA  
developed by PhytoHealth



## Evidence of Efficacy

**24 Research Articles**  
on PG2 found in top 25%  
Leading Medical & Cancer  
Journals

**323 Trial Subjects**  
in a successfully  
conducted randomized,  
double-blind, multi-center  
clinical trial

**20 Clinical Data Reports**  
presented to world-  
renowned medical society  
including ASCO, MASCC,  
WCP, and TJCC



## Market Growth

**PG2 is reimbursed by Taiwan  
National Health insurance.**  
the 1<sup>st</sup> botanical drug  
reimbursed by NHI(2021.3)

**PG2 has been adopted by**  
115 Medical Institutions  
22 Medical Centers  
47 Regional Hospitals  
16 District Hospitals

**Continuous accumulation of clinical  
experience in cancer-related  
fatigue**

700+ Oncologist  
19,000+ Patient experience  
14,000+ Continuing education  
for medical staff



懷特生技新藥(股)公司  
PhytoHealth Corporation

# Sharing our Value Chain



懷特生技新藥(股)公司  
PhytoHealth Corporation



# 2024-2025 key progress



懷特生技新藥(股)公司  
PhytoHealth Corporation



# **1. PG2 15 Years Post-Launch: Establishing a Strong Presence in Taiwan, Accumulating Clinical Evidence, and Striving to Improve Cancer-Related Fatigue**



懷特生技新藥(股)公司  
PhytoHealth Corporation



# 92% of patients have cancer-related fatigue

## 92% 台灣癌症患者罹癌期間有疲憊問題

- 第一次全台灣癌症病患「癌因性疲憊症」流行病學調查研究
- 期間為2015年2月至5月
- 共23家醫院進行研究
- 共1,207病患參與調查
- 問卷  
癌因性疲憊(BFI-T, ICD-10)  
生活品質量表(FACT-G7)  
癌症症狀困擾嚴重度量表




罹癌期間有疲憊問題

2015 Palliative Care in Oncology Symposium, Boston; Oct 9-10, 2015, Abstract # 155471. 2016 MASCC Poster # MASCC-0488.

10

## 大於1/4 癌症病患有中重度疲憊



\* The three groups were calculated from the average of nine items from BFI and categorize into mild (<4), moderate (4-6.99), Severe (≥ 7).

2015 Palliative Care in Oncology Symposium, Boston; Oct 9-10, 2015, Abstract # 155471. 2016 MASCC Poster # MASCC-0488.

12

According to the "Guidelines of Management of Cancer related Fatigue<sup>1</sup>"  
**Astragals polysaccharide injection (PG2<sup>®</sup>)** is recommended to treat moderate to severe cancer related fatigue (Level 1A, Grade A Recommendation)


1. Management of Cancer Related Fatigue in Taiwan-An Evidence Based Consensus of screening, assessment and treatment: Japanese Journal of Clinical Oncology (JJCR 2022 Volume 53, Issue 1, January 2023). 2023. 11 台灣癌症安寧緩和醫學會 發表更新



懷特生技新藥(股)公司  
PhytoHealth Corporation



# 2025 PG2 15th Anniversary Symposium — Sustaining Milestones and Exploring Future Perspectives



懷特生技新藥(股)公司  
PhytoHealth Corporation

## 2. Expanding the Launch and Promotion (Oraphine)<sup>®</sup> Locally and Globally



懷特生技新藥(股)公司  
PhytoHealth Corporation



# Oraphine<sup>®</sup> - A Novel Oral Analgesic

## For Moderate to Severe Pain Management



全球第一個 Nalbuphine 口服劑型



專利技術提升口服生體可用率



服用後 15~30 分鐘內有效，Onset 快



呼吸抑制副作用具有天花板效應



低不良反應(相較於針劑劑型)  
低成癮性(相較於mu鴉片類止痛劑)



非管制藥品(美國、歐盟及台灣) 不須管制藥品處方籤





# Oraphine® 60mg@soft Capsule : The Ideal Oral Opioid for Multimodal Acute Postoperative Pain Relief



Oraphine® (nalbuphine HCl 60mg Soft Capsules)  
懷特痛寶® 軟膠囊  
Easy way to end pain now


Relieving Pain  
Brightening Lives

Relieve moderate to severe acute pain

PhytoHealth

- Target Self-Paid Postoperative Pain Management Market :  
Obstetrics & Gynecology  
Orthopedics Neurosurgery
- Expanding Adoption in Domestic Hospitals : Hualien Tzu Chi Hospital, Tri-Service General Hospital, Kaohsiung Veterans General Hospital, Cheng Hsin General Hospital, Mackay Memorial Hospital System, Shin Kong Hospital, and 30+ other hospitals currently in procurement and use.
- Building Real-World Evidence in Multimodal Postoperative Pain Control — Orthopedic Surgery (N=300)

# Starting the product registration process for the German market launch



Founded in Germany in 2008, the company operates 5 production facilities, generates over USD 500 million in annual revenue, employs 1,780 people, and sells its products in 38 countries worldwide.

- ✓ Q1 2025: Sales cooperation LOI signed
- ✓ Q4 2025: Start regulatory consultation for German product registration

**In 2023, the German analgesics market reached USD 186 million, and it is projected to grow to USD 305 million by 2033, with a compound annual growth rate (CAGR) of 5.07%.**



### 3. Enter food supplement market with the spirit of new drug research and development



懷特生技新藥(股)公司  
PhytoHealth Corporation

# Functional Foods Utilizing Patented Botanical Extraction Technology



黃耆多醣

3.0

超進化

rAPP 耆多醣®

高效品種 / 新藥技術食品化

黃耆萃取

未知品種 / 已破壁未純化

黃耆片

無效品種 / 熬煮沖泡破壁不全



懷特生技新藥(股)公司  
PhytoHealth Corporation



# Enhancing Brand Value and Fostering Business Partnerships

植物藥級 X 精準健康 =  懷特新藥

原料管控

B2B源頭掌握

品牌合作

強強聯手 借力使力

功效配方

B2B擴大觸及

創新商模 擴大合作



懷特品牌

滲透終端市場



懷特生技新藥(股)公司  
PhytoHealth Corporation

# Corporate Sustainability ESG

1 GRI Sustainability Reporting Standards

2 SASB Sustainability Accounting Standards

## Core Values

Clinical Education × Patient Care  
× Public Welfare Participation

Driving Sustainable Health Value Creation

## Annual Achievements

- Completed 2024 ESG report
- Completed SASB Standard Disclosure
- Completed Greenhouse Gas Inventory

## Clinical Education

- 600+ medical promotion events / 14,000+ participants
- Cancer-related fatigue: 350+ events / 10,000 participants
- Pain management: 200+ events / 3,000 participants
- 10+ health education news articles / multiple publications in medical journals

## Social engagement

- “Ride to Survive” Cycling Tour for Cancer Patients → Donation of Nutritional Supplies Pioneered
- 11 Cancer Public Art Installations: “Hope Figurines”

# Financial Information



懷特生技新藥(股)公司  
PhytoHealth Corporation

# 「Balance Sheet」

Sound financial structure  
1. Sufficient cash  
2. Low debts ratio

(Expressed in Thousands of New Taiwan Dollars)

Account	114.6.30	%	113.12.31	%
CURRENT ASSETS	1,495,557	64	1,306,393	54
NON-CURRENT	842,571	36	1,133,277	46
TOTAL ASSETS	2,338,128	100	2,439,670	100
CURRENT LIABILITIES	40,083	1	54,396	2
NON-CURRENT	16,867	1	16,894	1
TOTAL LIABILITIES	56,950	2	71,290	3
Share capital - ordinary	1,986,189	85	1,986,189	82
Capital surplus and Others	(140,612)	(6)	(84,829)	(4)
Equity-Parent Company	1,845,577	79	1,901,360	78
Minority	435,601	19	467,020	19
Total Equity	2,281,178	98	2,368,380	97
TOTAL LIABILITIES AND EQUITY	2,338,128	100	2,439,670	100



懷特生技新藥(股)公司  
PhytoHealth Corporation



# 「Income statement」

Net loss reduced by 17% compared with the same period last year

(Expressed in Thousands of New Taiwan Dollars)

Account	114年 1-6月		113年 1-6月		增減率%
	(A)	%	(B)	%	(A-B)/B
Net Sales	61,570	100	76,713	100	(20)
Gross Margin	19,563	32	30,161	39	(35)
Operating Exp.	(101,828)	(165)	(106,438)	(139)	(4)
Operating Loss	(82,265)	(133)	(76,277)	(100)	8
Non-operating gain/loss	17,444	28	12,106	16	44
Net loss before income tax	(64,821)	(105)	(64,171)	(84)	1
Net loss-consolidated	(64,806)	(105)	(64,171)	(84)	1
Net loss-Parent	(36,443)	(59)	(43,824)	(57)	(17)
EPS	(0.18)		(0.22)		



懷特生技新藥(股)公司  
PhytoHealth Corporation



**Thank You !**